C5AR1 and anti-neutrophil cytoplasmic antibody-associated vasculitis: CCX168, a selective C5aR1 inhibitor for ANCA-associated vasculitis, has demonstrated clinical efficacy [16], although its potential antitumour effects in oncology are yet to be explored [17–19].